Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

90.7K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
90.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.

Journal of psychopharmacology (Oxford, England)·2025
Same author

Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autism.

Neuropharmacology·2025
Same author

Nabiximols (NBX) suppresses tremor in a rat Harmaline model of essential tremor.

Experimental neurology·2024
Same author

Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT<sub>1A</sub> receptor biased agonist.

Naunyn-Schmiedeberg's archives of pharmacology·2024
Same author

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.

Journal of thrombosis and haemostasis : JTH·2023

Related Experiment Video

Updated: Apr 26, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.3K

Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the

Mary V Burke1, Christine Nocjar, Alex J Sonneborn

  • 1Research, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA; Interdepartmental Neuroscience Program, Yale University, New Haven, Connecticut, USA.

Journal of Neurochemistry
|July 31, 2014
PubMed
Summary

Serotonin-2C (5-HT2C) receptors in the striatum control dopamine release by influencing GABAergic activity in the substantia nigra. Blocking these receptors increases dopamine, suggesting a key role in neurological pathways.

Keywords:
GABAParkinson's diseasemicrodialysisstriatumsubstantia nigra

More Related Videos

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

50.6K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

2.6K

Related Experiment Videos

Last Updated: Apr 26, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.3K
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

50.6K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

2.6K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Serotonin-2C (5-HT2C) receptor agonists show therapeutic potential for obesity, depression, and Parkinson's disease.
  • 5-HT2C receptor stimulation is known to inhibit dopamine (DA) release, but the precise neural circuits and receptor locations are unclear.

Purpose of the Study:

  • To investigate the role of 5-HT2C receptors in the substantia nigra (SN) and caudate-putamen (CP) in regulating nigrostriatal DA release.
  • To determine the localization and functional contribution of 5-HT2C receptors to dopamine control.

Main Methods:

  • Dual-probe in vivo microdialysis in rats.
  • Systemic administration of a selective 5-HT2C agonist (Ro 60-0175).
  • Intrastriatal and intra-SN infusions of a selective 5-HT2C antagonist (SB 242084) and a GABA-A agonist (muscimol).

Main Results:

  • Systemic agonist administration decreased CP DA release.
  • Intrastriatal antagonist administration increased basal DA in the CP.
  • Antagonist infusions into the SN pars reticulata (SNpr) had modest effects, while GABA-A agonist infusions into the SNpr reversed the effects of striatal antagonist.

Conclusions:

  • 5-HT2C receptors in the striatum play a significant role in regulating nigrostriatal DA release.
  • Striatal 5-HT2C receptors likely exert their effects by modulating GABAergic activity within the SN.
  • This localized action suggests a specific therapeutic target for conditions involving dopamine dysregulation.